| Schedule of Segment Reporting Financial Information |
The following table presents selected financial information with respect to the Company’s single operating segment for the three months ended December 31, 2025 and 2024 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended December 31, |
|
|
|
2025 |
|
|
2024 |
|
Revenue |
|
|
|
|
|
|
Royalty revenue |
|
$ |
18,615 |
|
|
$ |
16,959 |
|
Total revenue |
|
|
18,615 |
|
|
|
16,959 |
|
Operating expenses: |
|
|
|
|
|
|
RSV |
|
|
4,921 |
|
|
|
18,415 |
|
Total virology |
|
|
4,921 |
|
|
|
18,415 |
|
KIT |
|
|
4,845 |
|
|
|
4,257 |
|
STAT6 |
|
|
7,101 |
|
|
|
2,287 |
|
MRGPRX2 |
|
|
2,257 |
|
|
|
2,077 |
|
Total immunology |
|
|
14,203 |
|
|
|
8,621 |
|
Early discovery |
|
|
1,579 |
|
|
|
359 |
|
Other programs for out-licensing |
|
|
156 |
|
|
|
261 |
|
Total other programs |
|
|
1,735 |
|
|
|
620 |
|
General and administrative |
|
|
9,009 |
|
|
|
12,846 |
|
Loss from operations |
|
|
(11,253 |
) |
|
|
(23,543 |
) |
Other income (expense): |
|
|
|
|
|
|
Interest expense |
|
|
(3,083 |
) |
|
|
(1,962 |
) |
Interest and investment income, net |
|
|
2,422 |
|
|
|
2,799 |
|
Total other (expense) income, net |
|
|
(661 |
) |
|
|
837 |
|
Loss before income taxes |
|
|
(11,914 |
) |
|
|
(22,706 |
) |
Income tax (expense) benefit |
|
|
(24 |
) |
|
|
416 |
|
Net loss |
|
$ |
(11,938 |
) |
|
$ |
(22,290 |
) |
|